Loading...
•
Jun 30
iRhythm Q2 2025 Earnings Report
iRhythm Technologies announced its second quarter 2025 financial results, reporting a significant increase in revenue and improved gross margin, alongside a reduced net loss.
Key Takeaways
iRhythm Technologies delivered a strong second quarter in 2025, achieving record quarterly revenue of $186.7 million, a 26.1% increase year-over-year. The company also improved its gross margin to 71.2% and significantly reduced its net loss to $14.2 million, demonstrating strong operational execution and growth across its core monitoring business and new channel partners.
Revenue for Q2 2025 reached a record $186.7 million, marking a 26.1% increase compared to Q2 2024.
Gross margin improved to 71.2% in Q2 2025, up 130 basis points from 69.9% in Q2 2024.
Net loss decreased to $14.2 million in Q2 2025, a significant improvement from a net loss of $20.1 million in Q2 2024.
Adjusted EBITDA for Q2 2025 was $15.7 million, a substantial increase from $5.0 million in Q2 2024.
iRhythm
iRhythm
iRhythm Revenue by Segment
iRhythm Revenue by Geographic Location
Revenue by Segment
Zio Services Revenue
CapyFin.comRevenue by Geographic Location
International Markets Revenue
CapyFin.com Forward Guidance
iRhythm Technologies has increased its fiscal year 2025 guidance for both revenue and adjusted EBITDA margin, reflecting confidence in continued growth and operational efficiency.
Positive Outlook
- Full year 2025 revenue is projected to be between $720 million to $730 million, an increase from previous guidance.
- Adjusted EBITDA margin for the full year 2025 is expected to range from approximately 8.0% to 8.5% of revenues, indicating improved profitability.
- Continued momentum in core long-term continuous monitoring business is expected to drive future growth.
- Sustained demand for Zio AT and progress within innovative value-based care accounts are anticipated.
- Strategic partnership with Lucem Health is expected to accelerate early identification of undiagnosed arrhythmias.
Challenges Ahead
- No specific negative forward guidance points were explicitly stated in the provided text.
- The company has not reconciled its adjusted operating expenses and adjusted EBITDA margin estimates for full year 2025 due to uncertainties.
- Future results could differ materially due to various risks and uncertainties, as mentioned in the forward-looking statements.
- The company disclaims any obligation to update forward-looking statements.
- Potential for increased blended cost per unit from a higher Zio AT product mix could impact future gross margins.